Cigna to Debut Rebate‑Free Pharmacy Benefits Model in 2027 as Express Scripts Gains Early Client Traction

Cigna revealed measurable momentum this week for its new rebate‑free pharmacy benefits model, “Signature,” offering a shift away from traditional PBM structures and gaining early client adoption ahead of its 2027 rollout.

During the Q2 2026 earnings call on July 30 — held less than two months ago — CEO Brian Evanko confirmed that the model is generating “significant early interest” from clients. The company plans to introduce Signature to Cigna Healthcare’s fully insured plans in 2027, with a broader rollout to Express Scripts clients in 2028. The model aims to enhance affordability, with Cigna projecting it could reduce members’ branded medication costs by approximately 30% per month.

Evanko also emphasized that 2027 selling season is already showing strength, calling it “one of our strongest selling seasons in recent years.”

This development arrives alongside strong Q2 performance: adjusted revenue for Cigna Healthcare reached $11.7 billion, up from $10.8 billion in the prior‑year quarter, while the Evernorth division played a complementary role in the improvement.

This shift underscores a strategic pivot: by decoupling PBM revenue from drug pricing, Cigna seeks to align more transparently with client and patient interests. The early traction suggests a receptive market response well ahead of full implementation.

Implications for Investors

As a significant component of Evernorth and its pharmacy benefits business, successful deployment of the Signature model could meaningfully bolster Cigna’s margin profile, particularly if the anticipated 30% savings translate into stronger client contracts and volume adoption.

The move also signals Cigna’s continued reshaping of its portfolio. Coupled with its exit from ACA individual and Medicare Advantage plans, the firm is increasingly focusing on core strengths like employer-sponsored healthcare and specialty services.

What to Watch Next

• The response from clients during 2027’s selling season and adoption rates among Express Scripts customers beginning in 2028.
• Quarterly updates on cost savings and margin impact tied to the rebate‑free model.
• Competitive reactions in PBM and managed care landscapes — whether peers adopt similar models or differentiate strategies.

For Cigna (NYSE: CI), currently trading at approximately $282.52 with a slight net decline of 0.19% as of September 4, 2026, sustained momentum behind the Signature model could offer meaningful upside if implemented and scaled effectively.

Sources: Fierce Healthcare reporting CEO comments on early client interest and rollout timeline; Reuters coverage of broader strategic realignment and Q2 performance figures.